Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dice Therapeutics Inc (NQ: DICE ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Aug 8, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Dice Therapeutics Inc BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs September 01, 2023 Via Investor Brand Network Exposures Product Safety Why These 3 Large Caps Are Bucking the August Slump August 22, 2023 The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023. Via MarketBeat Topics Economy Stocks Exposures Fossil Fuels Interest Rates US Equities M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) July 26, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE July 10, 2023 From Kahn Swick & Foti, LLC Via Business Wire DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE June 21, 2023 From Kahn Swick & Foti, LLC Via Business Wire Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover June 21, 2023 The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer. Via MarketBeat Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments June 20, 2023 Via Spotlight Growth DICE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DICE Therapeutics, Inc. Is Fair to Shareholders June 20, 2023 From Halper Sadeh LLC Via Business Wire DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023 June 13, 2023 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights May 11, 2023 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference May 03, 2023 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference March 23, 2023 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights March 15, 2023 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting March 01, 2023 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics to Participate at Upcoming Investor Conferences February 08, 2023 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference January 04, 2023 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights November 09, 2022 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics to Present at Upcoming Investor Conferences November 03, 2022 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares October 17, 2022 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Announces Pricing of Upsized Public Offering of Common Stock October 12, 2022 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Announces Proposed Public Offering of Common Stock October 11, 2022 From DICE Therapeutics, Inc. Via GlobeNewswire DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis October 11, 2022 From DICE Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.